Monthly Archives: June 2020

ILN Today Post

HR BRIEF: HOW WILL THE FURLOUGH SCHEME CHANGE FROM 1ST JULY 2020?

Further to the recently announced changes to the furlough scheme (see our blog on this), detailed guidance has now been published by the government. In this briefing, we look at some key questions relating to the changes.

WHICH EMPLOYEES ARE ELIGIBLE?

The general eligibility requirements as were already in place have not been changed. Read more…

Read full article
ILN Today Post

CORONAVIRUS CRISIS BRIEFING

All information contain within this update is accurate at the time of publication. During these unprecedented times where the situation is constantly changing at pace it is vital that you take expert advice where necessary. Please do not hesitate to contact us if you wish to discuss any issues covered in these updates further. The Hill Brown Licensing Team and the wider team at Miller Samuel Hill Brown remain committed to providing the fullest possible service for the trade at this extremely challenging time. Read more…

Read full article

Lawyers: Think Outside the Box to Connect with Your Network

It’ 2020. Many of us had grand plans for the way that our business development and relationship building was going to go this year. We were going to spend the year connecting, deepening our engagement, forging new contacts!

I won’t remind you what threw a wrench in that.

But engagement isn’t over.

Read full article

The Latest COVID-19 Reopening Guidance for Illinois and Chicago Employers

Last week, Illinois moved in to “Phase 4” of the state’s five-stage Restore Illinois Plan (the “Plan”). As part of this transition, the Illinois Department of Commerce and Economic Opportunity issued updated, industry-specific Phase 4 Guidelines (the “Guidelines”).

From an employer compliance standpoint, the transition from Phase 3 to 4 is not a radical change. Rather, the transition primarily involves loosened restrictions for already open businesses, and the reopening of additional industries (such as indoor recreation facilities like bowling alleys and skating rinks). Social distancing and other guidelines introduced in Phase 3 remain in effect. For an in-depth review of these guidelines, please see our advisory on Illinois and Chicago’s Phase 3 Reopening Guidance.

Read full article

Every HIPAA Waiver Has Its Thorn

On March 17, 2020, the Office for Civil Rights’ (“OCR”) announced that—for the duration of the COVID-19 emergency—it would exercise enforcement discretion and waive any potential penalties for HIPAA violations relating to health care providers’ use of “everyday communications technologies” in the provision of services via telehealth (the “HIPAA Waiver”). This move has resulted in a drastic increase in the number of telehealth encounters. The HIPAA Waiver has enabled many providers to immediately leverage these technologies to render services via telehealth for the first time, without the need to expend significant resources to quickly ramp up a HIPAA-compliant telehealth platform. A summary of the HIPAA Waiver can be found in a recent blog post. While the HIPAA Waiver applies only temporarily, it is likely that the increased reliance on telehealth evidenced over the past three months is here to stay.

Read full article

Video: Health Care Employers Face Reopening Challenges – Employment Law This Week

Featured in #WorkforceWednesday: Attorney Denise Dadika examines the unique challenges health care employers face as they ramp business back up and reopen for both patients and employees.

Read full article

NJ Governor Again Increases Permissible Size of Gatherings and Clarifies the Meaning of “Outdoor Area” for Purposes of Outdoor Dining

On June 22, 2020, New Jersey Governor Phil Murphy issued Executive Order 156  (“EO 156”), which, effective immediately, increases the permissible number of attendees at indoor and outdoor gatherings from the limits he established in Executive Order 152  (“EO 152”) (which we wrote about here).

Read full article

New explanations of the FAS Russia on certain aspects of advertising in the field of pharmaceuticals and healthcare

The latest Explanations of the FAS Russiaconcern the following:

1. REFERENCE TO LICENSE 

Specification of the information about the license is not required directly in the advertising of medical activities that are subject to licensing. Verification of the presence of relevant documents is carried out at the request of the advertising distributor in accordance with article 13 of the Law on advertising. The advertiser, in turn, shall provide reports, including information about the availability of a license, mandatory certification and state registration.

Read full article

Estates, Wills and Trusts: RSS Welcomes Notary Myriam Léger

June 29, 2020 — RSS is pleased to welcome a new member in our Estates, Wills and Trusts Practice Group. Myriam Léger became a notary in 2016. Prior to joining RSS, she was practising in her own firm.

“Myriam’s profile is ideally suited to our team”, says her colleague William Dion-Bernard, also a notary. “She has accumulated a most diversified experience that fits perfectly with our practice.”

Read full article

Current Good Manufacturing Practices in the Time of COVID-19: FDA Announces New Expectations on Risk Assessment and Risk Management

FDA recently published its “Good Manufacturing Practice Considerations for Responding to COVID-19 Infection in Employees in Drug and Biological Products Manufacturing Guidance for Industry” (“Guidance”) which provides suggestions on managing the potential risk of products being contaminated by SARS-CoV-2, the virus behind COVID-19 infections for drug and biological product manufacturers, 503B outsourcing facilities, and 503A compounding pharmacies.

The Guidance builds on the current Good Manufacturing Practices (cGMPs) regulations for drugs and biological products, which require personnel with an illness that could adversely affect drug safety or quality be excluded from direct contact with drugs and drug components used in manufacturing.[1]  As the Guidance states, preliminary research indicating that SARS-CoV-2 “is stable for several hours to days in aerosols and on surfaces,” and that it has an incubation period of 2 to 14 days, which are both factors that increase the risk of spread and introduction into products.  The actual health risk is hard to calculate – FDA itself notes that there have not been documented transmissions through pharmaceuticals to date.  The regulatory risk, however, is an easier formula – FDA has a clear expectation that drug and biological product manufacturers evaluate the potential for COVID-19 contamination of their products under existing controls, or risk being out of compliance with cGMPs.

Read full article